Skip to main content
. 2017 Dec 1;7(12):2587–2599.

Table 1.

Clinical-pathological and molecular characteristic of study populations, n (%)

A. CTC cohort
Variable Value %
No. of patients 47 100
Median age (yr, range) 52, 25-71
    Age
        < 50 years 19 40.4
        ≥ 50 years 28 59.6
    Sex
        Female 22 46.8
        Male 25 53.2
    Primary tumor site
        Ascending 12 25.5
        Transverse 1 2.1
        Descending 7 14.9
        Sigmoid 22 46.8
        Rectum 5 10.6
    Line of anti-EGFR Rx
        1st line 6 12.8
        2nd line 26 55.3
        3rd line 15 31.9
    Previous treatment
        Irinotecan 20 42.6
        Oxaliplatin 40 85.1
        Bevacizumab 36 76.6
    Chemotherapy regimen
        Anti-EGFRab monotherapy 8 17.0
        Irinotecan-based+anti-EGFRab 35 74.5
        Oxaliplatin-based+anti-EGFRab 2 4.3
        Vemurafenib+Cetuximab+irinitocan 2 4.2
    Liver metastasis
        No 11 23.4
        Yes 36 76.6
    Lung metastasis
        No 21 44.7
        Yes 26 55.3
    Differentiated
        Moderate 40 85.1
        Poorly 7 14.9
    NRAS
        wt 41 87.2
        mt 2 4.3
        No data 4 8.5
    BRAF
        wt 39 83
        mt 6 12.8
        No data 2 4.3
    PIK3CA
        wt 33 70.2
        mt 4 8.5
        Variant 2 4.3
        No data 8 17
    MSI
        MSS/MSI-L 35 74.5
        MSI-H 3 6.4
        No data 9 19.1
B. Tissues cohort
Variable Value %
No. of patients 176 100
Median age (yr, range) 55, 20-79
    Age
        < 50 years 51 29
        ≥ 50 years 125 71
    Sex
        Female 79 44.9
        Male 97 55.1
    Primary tumor site
        Ascending 50 28.4
        Transverse 14 8
        Descending 10 5.7
        Sigmoid 66 37.5
        Rectum 36 20.5
    Type of tissue tested
        Primary CRC tissues 156 88.6
        Metastatic tissues 20 11.4
    Line of anti-EGFR Rx* (n = 74)
        1st line 8 10.8
        2nd line 34 45.9
        3rd line 32 42.3
    Previous treatment* (n = 74)
        Irinotecan 42 56.8
    Differentiated
        Moderate 109 61.9
        Poorly 64 36.4
        Unknown 3 1.7
    KRAS
        wt 127 72.2
        mt 48 27.3
        No data 1 0.6
    NRAS
        wt 140 79.5
        mt 4 2.3
        No data 32 18.2
    BRAF
        wt 136 77.3
        mt 24 13.6
        No data 16 9.1
    PIK3CA
        wt 132 75
        mt 19 10.8
        No data 25 14.2
    MSI
        MSS/MSI-L 98 55.7
        MSI-H 7 4
        No data 71 40.3
*

only the patients that confirmed RASwt and treated with anti-EGFR agents.

wt: wild type, mt: mutation.